VSTM Verastem, Inc.
Pharmaceutical Preparations · Nasdaq · SEC CIK 1526119 · Fiscal year ends 12/31
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY—
TTM net income YoY25.8%
TTM EPS YoY57.0%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—
Margins
Gross margin—
Operating margin-193.7%
Net margin-178.4%
FCF margin—
EBITDA margin—
Returns
ROE—
ROA-88.0%
ROIC (approx.)—
Asset turnover0.49x
Leverage & solvency
Liabilities / assets95.6%
Debt / equity0.00x
Current ratio1.93x
Interest coverage-141.93x
Cash quality & payout
Operating cash flow / net income0.89x
Accruals ratio-9.5%
Payout ratio—
Capex / revenue—
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | 2026Q32026-09-30 | 2026Q22026-06-30 | 2026Q12026-03-31 | 2025Q4*2025-12-31 | 2025Q32025-09-30 | 2025Q22025-06-30 | 2025Q12025-03-31 | 2024Q4*2024-12-31 |
|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||
| Revenue | $24.01M | $40.08M | $18.67M | $17.54M | $11.24M | $2.14M | — | $0 |
| R&D expense | $68.81M | $41.34M | $38.22M | $31.67M | $28.99M | $24.79M | $29.15M | $20.81M |
| SG&A expense | $26.48M | $27.41M | $22.30M | $24.44M | $21.01M | $20.67M | $15.02M | $10.78M |
| Operating income | -$75.22M | -$32.71M | -$44.90M | -$41.48M | -$40.72M | -$43.76M | -$44.17M | -$31.59M |
| Interest expense | $212,000 | $360,000 | $382,000 | $415,000 | $319,000 | $212,000 | $192,000 | $1.15M |
| Pretax income | -$74.72M | -$33.86M | — | -$32.92M | -$98.52M | -$25.93M | — | — |
| Income tax | $0 | $816,000 | $0 | — | $0 | $0 | $0 | $185,000 |
| Net income | -$74.72M | -$34.67M | -$36.59M | -$32.92M | -$98.52M | -$25.93M | -$52.10M | -$64.55M |
| EBITDA | — | — | — | -$41.46M | -$40.71M | -$43.76M | -$44.16M | -$31.58M |
| EPS (basic) | -0.74 | -0.35 | -0.37 | — | -1.35 | -0.39 | -0.96 | — |
| EPS (diluted) | -0.74 | -0.35 | -0.46 | — | -1.35 | -0.62 | -0.96 | — |
| Weighted avg. shares (diluted) | 101.24M | 100.12M | 99.15M | — | 73.16M | 74.04M | 54.17M | — |
| Balance sheet | ||||||||
| Cash & equivalents | $172.80M | $136.35M | $165.55M | $204.99M | $137.95M | $164.56M | $117.81M | $89.06M |
| Short-term investments | — | — | $16.13M | — | — | — | — | — |
| Inventory | $2.25M | $2.40M | $2.29M | $1.83M | $1.79M | $1.17M | — | — |
| Current assets | $199.38M | $176.16M | $202.90M | $223.41M | $154.06M | $174.27M | $124.70M | $94.96M |
| PP&E, net | — | — | — | — | $20,000 | $21,000 | $22,000 | $32,000 |
| Intangibles | $15.59M | $15.87M | $16.15M | $16.43M | $16.70M | $15.64M | — | — |
| Total assets | $229.64M | $206.51M | $227.81M | $246.44M | $176.85M | $196.26M | $131.70M | $101.54M |
| Current liabilities | $103.33M | $78.13M | $66.84M | $72.27M | $59.71M | $50.36M | $35.62M | $30.97M |
| Long-term debt | — | — | — | — | — | — | — | $40.72M |
| Total debt | — | — | — | — | — | — | — | $40.72M |
| Total liabilities | $219.54M | $156.53M | $146.03M | $189.25M | $192.38M | $160.21M | $164.13M | $130.43M |
| Shareholders' equity | $10.10M | $49.99M | $81.78M | $57.20M | -$15.53M | $36.06M | -$32.43M | -$28.89M |
| Net debt | — | — | — | — | — | — | — | -$48.34M |
| Shares outstanding | 94.47M | 90.48M | 87.84M | 77.74M | 66.75M | 61.52M | 51.49M | 44.78M |
| Cash flow statement | ||||||||
| Operating cash flow | -$33.59M | -$43.91M | -$52.12M | -$29.95M | -$36.22M | -$32.66M | -$38.68M | -$25.10M |
| Capital expenditure | — | — | — | — | — | — | — | $0 |
| Free cash flow | — | — | — | — | — | — | — | -$25.10M |
| Investing cash flow | -$7.50M | $16.25M | -$16.02M | -$1.34M | — | — | — | $0 |
| Financing cash flow | $77.54M | -$1.54M | $28.69M | $98.58M | $17.88M | $79.42M | $67.43M | $742,000 |
| Depreciation & amortization | — | — | — | $18,000 | $2,000 | $0 | $10,000 | $7,000 |
| Stock-based compensation | $3.71M | $3.43M | $2.05M | $2.02M | $2.18M | $3.41M | $1.79M | $2.02M |
Free plan shows the latest 8 periods; Pro shows all 63 🔒
· This company does not report gross profit in XBRL.
· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-21 06:27.